ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
30 mai 2024 07h15 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies...
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
04 avr. 2024 07h00 HE
|
ADC Therapeutics SA
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all...
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
03 avr. 2024 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024,...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
01 avr. 2024 16h05 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of...
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
04 janv. 2024 07h15 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that...
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
12 déc. 2023 05h15 HE
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
02 nov. 2023 10h10 HE
|
ADC Therapeutics SA
Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated...
ADC Therapeutics to Participate in September Investor Conferences
05 sept. 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in...
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
30 août 2023 19h33 HE
|
ADC Therapeutics SA
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in...
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
08 août 2023 07h00 HE
|
ADC Therapeutics SA
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio...